Oñate, GuadalupeBataller, AlexGarrido, AnaHoyos Colell, MontserratArnan, MontserratVives, SusanaColl, RosaTormo, MarSampol, AntoniaEscoda, LourdesSalamero, OlgaGarcia, AntoniBargay, JoanAljarilla, AlbaNomdedeu, Josep F.Esteve Reyner, JordiSierra, JorgePratcorona, Marta2022-03-042022-03-042021-09-132473-9537https://hdl.handle.net/2445/183760The negative prognostic impact of internal tandem duplication of FLT3 (FLT3-ITD) in patients with acute myeloid leukemia with mutated NPM1 (AML-NPM1) is restricted to those with a higher FLT3-ITD allelic ratio (FLT3(high); >= 0.5) and considered negligible in those with a wild-type (FLT3WT)/low ITD ratio (FLT3low). Because the comutation of DNMT3A (DNMT3A(mut)) has been suggested to negatively influence prognosis in AMLNPM1, we analyzed the impact of DNMT3A(mut) in FLT3-ITD subsets (absent, low, and high ratios). A total of 164 patients diagnosed with AML-NPM1 included in 2 consecutive CETLAM protocols and with DNMT3A and FLT3 status available were studied. Overall, DNMT3A(mut) status did not have a prognostic impact, with comparable overall survival (P = .2). Prognostic stratification established by FLT3-ITD (FLT3WT = FLT3low > FLT3(high)) was independent of DNMT3A(mut) status. Measurable residual disease (MRD) based on NPM1 quantitative polymerase chain reaction was available for 94 patients. DNMT3A(mut) was associated with a higher number of mutated NPM1 transcripts after induction (P = .012) and first consolidation (C1; P < .001). All DNMT3A(mut) patients were MRD+ after C1 (P < .001) and exhibited significant MRD persistence after C2 and C3 (MRD+ vs MRD-; P = .027 and P = .001, respectively). Finally, DNMT3A(mut) patients exhibited a trend toward greater risk of molecular relapse (P = .054). In conclusion, DNMT3A(mut) did not modify the overall prognosis exerted by FLT3-ITD in AML-NPM1 despite delayed MRD clearance, possibly because of MRD-driven preemptive intervention.9 p.application/pdfengcc by-nc-nd (c) Oñate, Guadalupe et al, 2021http://creativecommons.org/licenses/by-nc-nd/3.0/es/Leucèmia mieloideEnzimsMyeloid leukemiaEnzymesinfo:eu-repo/semantics/article2022-03-03info:eu-repo/semantics/openAccess34516636